Older age and certain health conditions increase risk of death from COVID-19 in boosted individuals

Spread the love

Coronavirus disease 2019 (COVID-19) vaccination has played a key role in reducing severe infections, morbidity and mortality during the pandemic.

However, certain patient groups still face a high risk of death from COVID-19 even after receiving a primary course of vaccination. Additionally, vaccine efficacy may decline over time.

To address these concerns and overcome severe outcomes, booster doses have been introduced along with other infection precautions that have been relaxed.

In a recent study posted on medRxiv* Researchers have identified a group of adults who have received a second booster dose in the UK who are at high risk of dying from COVID-19.

study: Risk of death from COVID-19 among adults who received a COVID-19 booster vaccine: a national retrospective cohort study of 14.6 million people in the United Kingdom. Image credit: Shutterstock.com

*Important Notices: medRxiv Publishes preliminary scientific reports that have not been peer-reviewed and should therefore not be considered definitive, to guide clinical practice or health-related actions, or to be treated as established information. not.

About research

Researchers used individual-level data from the 2021 Census linked to various health records to explore the association between COVID-19 booster doses and mortality outcomes in the United Kingdom. . The linked dataset contained information on her 52 million people, who make up 91.8% of the population.

The study population consisted of individuals aged 50-100 years who received a COVID-19 booster after September 1, 2022. Boosters are administered at least 84 days after the most recent clinically acceptable dose, and all patients receive at least two doses of vaccine prior to the booster dose.

The primary outcome was death from COVID-19, identified by a specific International Classification of Diseases (ICD) code on the death certificate. A secondary outcome was non-COVID-19 mortality. Individuals were monitored from 14 days after booster until April 11, 2023, death, or the end of the study period.

Medical conditions were identified using defined primary care records utilized in the QCovid2 risk prediction model. These data were collected from March 1, 2015 to March 21, 2021. Missing census features were determined by nearest-neighbour donor imputation. This is the methodology that the Office of National Statistics (ONS) adopted for his 2011 Census variables. Missing body mass index (BMI) data were managed by adding a “missing” category.

A cause-specific Cox regression analysis was performed to determine the association between each health comorbidity and the risk of death from COVID-19, as well as mortality from all other causes. Models adjusted for age, sex, and chronological time were used, with additional adjustments for ethnicity, region, BMI, and disability.

Older age and health condition increase the risk of death from COVID-19 in boosted individuals

The study involved 14,651,440 people aged 50-100 years, with a mean age of 67.9 years. Of the study population, 90.4% were British Caucasian and 46.9% were male.

From 1 September 2022 to 11 April 2023, 150,075 non-COVID-19 deaths and 6,800 COVID-19 deaths were reported. The average age of deaths due to the new coronavirus infection was 84 years old, and the average age of deaths other than the new coronavirus infection was 82.3 years old.

Age is an important predictor, with risk increasing with increasing age. Women had a lower risk of death than men.

Black Caribbean, Indian, and other ethnic groups had a lower risk of death from COVID-19 than white British groups. Morbid obesity or underweight increases the risk of COVID-19 and non-COVID-19 death.

Some health conditions include: learning disabilities or Down’s syndrome, pulmonary hypertension or fibrosis, motor neuron disease, multiple sclerosis, bone marrow and blood cancers, myasthenia or Huntington’s disease, Parkinson’s disease, COVID-19 It was associated with a higher risk of infection-related death. , lung or oral cancer, dementia, cirrhosis.

Certain conditions such as blood and bone marrow cancer, chronic kidney disease, cystic fibrosis, pulmonary hypotension and fibrosis, systemic lupus erythematosus, and rheumatoid arthritis are also associated with COVID-19 compared to non-COVID-19. was associated with a higher relative risk of death from disease-19 deaths.

In supplemental analyzes not adjusted for other health conditions, the risk of COVID-19 outcome was higher than in models that considered other health conditions. Notably, the risk of asthma was lower in models adjusted for other health conditions. However, in a supplementary analysis, those diagnosed with asthma had a significantly higher risk of death.

Conclusion

To effectively manage the risk of COVID-19, it is important to prioritize the most vulnerable groups for booster vaccination. According to the authors, this study was the first to examine the risk of death from COVID-19 versus non-COVID-19 in adults who received a booster dose in the fall of 2022.

Certain patient groups were at particularly high risk of death from COVID-19 compared with death from other causes. Therefore, these groups should be prioritized for subsequent vaccination, therapy and innovative treatments.

In addition, researchers highlight risks associated with various health conditions and sociodemographic characteristics. Taken together, this information can provide policy makers and other researchers with information on key demographics of interest in future research and vaccination efforts.

*Important Notices: medRxiv Publishes preliminary scientific reports that have not been peer-reviewed and should therefore not be considered definitive, to guide clinical practice or health-related actions, or to be treated as established information. not.

#Older #age #health #conditions #increase #risk #death #COVID19 #boosted #individuals


Spread the love

Leave a Comment